Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia

Authors:
  • C(Czech Leukemia Study Group ‐ for Life (CELL)
    Czech Leukemia Study Group ‐ for Life (CELL)

Abstract
Objective: To evaluate the prognostic power of minimal residual disease (MRD) monitored by polymerase chain reaction at defined time points during early treatment in adult patients with acute lymphoblastic leukemia (ALL).Methods: Seventy‐one patients were treated according to the GMALL 07/2003 protocol and evaluated for MRD in bone marrow by specific clonal rearrangements of Ig/TCR in BCR‐ABL negative ALL or fusion gene transcript in BCR‐ABL positive ALL.Results: Three‐year overall survival (OS) was 94% in patients with BCR‐ABL negative ALL reaching complete molecular response (CMR) after the first course of chemotherapy (vs. 32% if MRD >10−4; P = 0.001). Patients with CMR prior to the start of consolidation chemotherapy at week 11 had 3‐yr OS 82% (vs. 18% if MRD >10−4; P = 0.001). Patients with BCR‐ABL positive ALL showed slower MRD dynamics. There was a trend to better OS in patients with ≥4 log reduction of BCR‐ABL transcript prior to HSCT (92% vs. 50%; P = 0.065). None of the patients with detectable MRD (both BCR‐ABL positive and negative) after HSCT survived 3 yr.Conclusion: Early MRD kinetics is an important tool for new prognostication models with direct clinical impact irrespective of standard prognostic factors in patients with BCR‐ABL negative ALL.
Funding Information
  • Ministerstvo Zdravotnictví Ceské Republiky

This publication has 24 references indexed in Scilit: